Company Filing History:
2 out of 66 
1 out of 50 
Years Active: 2024-2025
Title: The Innovative Contributions of Stephen Michael Burleigh
Introduction
Stephen Michael Burleigh is a notable inventor based in Seattle, WA. He has made significant contributions to the field of biotechnology, particularly in the development of engineered immune cells. With a total of 2 patents, Burleigh's work focuses on advancing cancer immunotherapy and enhancing the efficacy of immune responses.
Latest Patents
Burleigh's latest patents include groundbreaking innovations such as "Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods." This patent describes engineered immune cells, specifically T cells, that express a chimeric receptor with a CD3zeta signaling domain. The engineered cells can be utilized in cell therapy, particularly in cancer immunotherapy through the adoptive transfer of these cells. Another significant patent is for "HPV-specific binding molecules," which includes TCRs and antibodies that target human papillomavirus (HPV) 16. This patent outlines methods for treatment using these binding molecules and engineered cells.
Career Highlights
Throughout his career, Burleigh has worked with prominent companies in the biotechnology sector. He has been associated with Juno Therapeutics GmbH and Editas Medicine, Inc., where he has contributed to innovative research and development efforts. His work has been instrumental in pushing the boundaries of what is possible in immunotherapy.
Collaborations
Burleigh has collaborated with notable professionals in his field, including Christopher Heath Nye and Cameron Brandt. These collaborations have further enriched his research and development endeavors, leading to advancements in the biotechnology landscape.
Conclusion
Stephen Michael Burleigh's contributions to biotechnology and immunotherapy are noteworthy. His innovative patents and collaborations reflect his commitment to advancing medical science and improving treatment options for patients. His work continues to inspire future innovations in the field.